Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Ribociclib Delays Quality of Life Deterioration in Advanced Breast Cancer

Study: MONALEESA-3 | Design: Phase III, Randomized, Double-blind | Population: HR+/HER2- Advanced Breast Cancer

"Adding ribociclib to fulvestrant maintains Health-Related Quality of Life (HRQOL) while significantly prolonging progression-free survival. The data reveals a 'risk paradox': despite added therapy, the time to definitive deterioration is delayed."

Study Design & Patient Flow

Randomization 2:1 (Ribociclib + Fulvestrant vs. Placebo + Fulvestrant)

Risk of Deterioration (Hazard Ratios)

Hazard Ratios < 1.0 favor Ribociclib. The data shows a consistent trend towards delayed deterioration across Global Health, Pain, and Physical Functioning.

Median Time to Deterioration (Months)

Patients on Ribociclib maintained their Global Health Status longer (35.9 months) compared to Placebo (33.1 months).

Baseline Comparability (EORTC QLQ-C30)

Baseline scores were well-balanced, ensuring that subsequent differences in deterioration are treatment-related. (Global Health: Higher is better; Pain: Lower is better).

Key Performance Indicators (Hazard Ratios)

Global Health Status

0.81
HR for TTD ≥10%
95% CI: 0.62–1.1

Pain Severity

0.77
HR for TTD ≥10%
95% CI: 0.57–1.05

Physical Functioning

0.82
HR for TTD ≥10%
95% CI: 0.61–1.10

Conclusion: The Risk Paradox

Typically, adding a new agent increases toxicity. Here, Ribociclib delays the deterioration of quality of life, likely due to better disease control (PFS benefit).

Appendix: Raw Data & Provenance

Metric Group Value Source

DOI:

Citation:

Selected: none

AI edit element

Describe the change you want. Optional: attach an image.
No image attached

Theme

👀 View Mode